BioSpace News Archive

CAD 10M financing arrangement with Tetra Bio-Pharma (TBP).

Evoke Pharma, Inc. announced that its flagship product, GIMOTI has been nominated for Healio’s Annual Disruptive Innovators Awards under the Healio Industry Breakthrough Award category.

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that Angelos Stergiou, MD, ScD. h.c, President and Chief Executive Officer of SELLAS, will participate in the Cantor Oncology, Hematology, HemeOnc Conference.

Gracell Biotechnologies Inc. announced that the management team will participate in and attend one-on-one meetings at three investor conferences in September 2022 as follows.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the appointment of Julie VanOrsdel Daves, MSHS, CCRP, as Senior Vice President (SVP), Clinical Development Operations.

Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival, today provided an update on its research and development programs for its expanded portfolio of immuno-oncology assets, and outlined its forward-looking clinical development goals for the next two years.

We are pleased to announce World Cord Blood Day 2022 (WCBD 2022) will take place on November 15th, featuring a free online medical conference and educational events worldwide.

Danimer Scientific, Inc. (NYSE: DNMR) (“Danimer” or the “Company”) chief executive officer Stephen Croskrey will be taking part in a high-level Summit on Biotechnology & Biomanufacturing for the American Bioeconomy, being hosted today by the White House Administration.

Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its CLIA/CAP-certified laboratory Provista Diagnostics has initiated a validation plan for PCR-based polio testing.

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (“A.I.”) and machine learning (“M.L.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it will present positive preclinical data on the in vivo efficacy of its drug candidate LP-184 for pancreatic cancer at the American Association for Cancer Research (AACR) Special Conference for Pancreatic Cancer.